Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,470.00GBp
24 Dec 2014
Price Change (% chg)

-63.00p (-1.39%)
Prev Close
4,533.00p
Open
4,521.00p
Day's High
4,533.00p
Day's Low
4,465.00p
Volume
295,887
Avg. Vol
3,096,938
52-wk High
5,470.00p
52-wk Low
2,806.02p

SHP.L

Chart for SHP.L

About

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in... (more)

Overall

Beta: 0.64
Market Cap (Mil.): £26,861.69
Shares Outstanding (Mil.): 590.00
Dividend: 2.24
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 19.78 38.19 38.61
EPS (TTM): 2.30 -- --
ROI: 27.96 19.00 18.27
ROE: 39.52 19.75 19.14
Search Stocks

Exclusive: Paulson & Co takes stake in Salix on heels of inventory issues - sources

- Hedge fund Paulson & Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter.

18 Dec 2014

EXclusive: Paulson & Co takes stake in Salix on heels of inventory issues - sources

- Hedge fund Paulson & Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter.

18 Dec 2014

Shire considering bid for NPS Pharmaceuticals: Bloomberg

- Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

Deals of the day- Mergers and acquisitions

(Adds Shire, Carrefour, Clessidra, CMVM, Snam, Eni, Lala, Lucchini and KGHM)

17 Dec 2014

Shire considering bid for NPS Pharmaceuticals: Bloomberg

- Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

Shire considering bid for NPS Pharmaceuticals - Bloomberg

Dec 17 - Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

BRIEF-Argen-X says partner Shire advances therapeutic antibody alliance

* arGen-X NV announces advancement of therapeutic antibody alliance with Shire

11 Dec 2014

Shire CEO eyes deals, but no urgency to spend AbbVie breakup fee

NEW YORK - Shire PLC's chief executive said he sees no urgency to spend the windfall the Dublin-based drugmaker received when AbbVie walked away from a $55 billion takeover bid earlier this year.

10 Dec 2014

Shire teams up with foundation to tackle cystic fibrosis

LONDON - Pharmaceutical company Shire said it would work with a specialist cystic fibrosis foundation on developing a technology to improve patients' lung function and reduce infections.

10 Dec 2014

Shire teams up with foundation to tackle cystic fibrosis

LONDON, Dec 10 - Pharmaceutical company Shire said it would work with a specialist cystic fibrosis foundation on developing a technology to improve patients' lung function and reduce infections.

10 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks